Alkermes PLC (NASDAQ: ALKS) is one of 197 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its competitors? We will compare Alkermes PLC to related companies based on the strength of its institutional ownership, earnings, analyst recommendations, risk, valuation, dividends and profitability.
This is a breakdown of current ratings and recommmendations for Alkermes PLC and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Alkermes PLC Competitors||472||2243||6139||118||2.66|
Alkermes PLC presently has a consensus price target of $63.25, indicating a potential upside of 25.77%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 0.80%. Given Alkermes PLC’s higher probable upside, equities analysts clearly believe Alkermes PLC is more favorable than its competitors.
Insider & Institutional Ownership
98.5% of Alkermes PLC shares are held by institutional investors. Comparatively, 48.6% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 5.3% of Alkermes PLC shares are held by company insiders. Comparatively, 14.0% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Volatility & Risk
Alkermes PLC has a beta of 2.2, suggesting that its stock price is 120% more volatile than the S&P 500. Comparatively, Alkermes PLC’s competitors have a beta of 1.63, suggesting that their average stock price is 63% more volatile than the S&P 500.
Earnings and Valuation
This table compares Alkermes PLC and its competitors revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Alkermes PLC||$804.37 million||-$103.30 million||-39.29|
|Alkermes PLC Competitors||$207.78 million||-$2.31 million||0.50|
Alkermes PLC has higher revenue, but lower earnings than its competitors. Alkermes PLC is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This table compares Alkermes PLC and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Alkermes PLC Competitors||-4,697.97%||-120.52%||-44.48%|
Alkermes PLC beats its competitors on 7 of the 12 factors compared.
Alkermes PLC Company Profile
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company’s products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company’s product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.
Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with MarketBeat.com's FREE daily email newsletter.